Gilead’s remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data the World Health Organization (WHO) accidentally posted on its website.

In response to the leaked results, since taken down by the WHO, Gilead said that the trial was stopped early and so findings remain inconclusive.

In a statement, Gilead noted that the WHO posting included inappropriate characterisations of the study, stopped early due to low enrolment and cannot be used for ‘statistically meaningful conclusions’.

In addition, the company added: “As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.

“We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future.”

Read more

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.